论文部分内容阅读
新近合成的1-脱氨基-8-D-精氨酸加压素(DDAVP)是天然加压素的改良制剂,具有较强的抗利尿作用,而无对血管等的付作用,为尿崩症的治疗药物。有人发现该药可使血浆第Ⅷ因子活性和前纤维蛋白溶解酶活化素(PA)升高,因此最近已被用于血友病甲和血管性假血友病的治疗。本文报道作者的实验及临床应用结果。研究对象为7名健康人和4例轻型血友病甲患者。一次静脉注射DDAVP10微克(溶于20毫升生理盐水中,10分钟注完),于注射前及注射后的不同时间测定其PA、凝血酶时间、连续凝血酶时间(STT)、活化的部分凝血活酶时间、第Ⅷ因子活性、第Ⅷ因子样抗原、纤维蛋白原、纤维蛋白降解
The newly synthesized 1-deamino-8-D-arginine vasopressin (DDAVP) is an improved preparation of natural vasopressin with a strong anti-diuretic effect without any adverse effects on blood vessels, Symptomatic treatment drugs. It has been found that the drug can make plasma factor VIII activity and pre-fibrinolytic enzyme activin (PA) increased, and therefore has been recently used for the treatment of hemophilia A and von Willebrand disease. This article reports the author’s experiments and clinical application results. The subjects were 7 healthy individuals and 4 mild hemophilia A patients. One intravenous injection of DDAVP 10 μg (dissolved in 20 ml of normal saline for 10 min) was used to measure PA, thrombin time, continuous thrombin time (STT) and activated partial thromboplastin time before and after injection Enzyme time, factor Ⅷ activity, factor Ⅷ antigen, fibrinogen, fibrin degradation